Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, et al. Guidelines for the diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720.

Article  PubMed  PubMed Central  Google Scholar 

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.

Article  PubMed  Google Scholar 

Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27(1):85–102.

Article  PubMed  Google Scholar 

Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15(3):155–60.

Article  CAS  PubMed  Google Scholar 

Bruix J, Sherman M. American Association for the study of liver D: management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

Article  PubMed  Google Scholar 

European Association For The Study Of The, European Organisation For L, Treatment Of R. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

Article  Google Scholar 

Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–43.

Article  PubMed  PubMed Central  Google Scholar 

Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.

Article  PubMed  Google Scholar 

Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773–96.

Article  PubMed  Google Scholar 

Liang L, Wang X, Huang S, Chen Y, Zhang P, Li L, Cui Y. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Front Immunol. 2023;14:1046771.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, Granito A. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023;23(3):279–91.

Article  CAS  PubMed  Google Scholar 

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90.

Article  CAS  PubMed  Google Scholar 

Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus Sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: a retrospective, real-world study. Heliyon. 2022;8(6):e09538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, et al. Lenvatinib plus Pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399–410.

Article  CAS  PubMed  Google Scholar 

Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–46.

Article  CAS  PubMed  Google Scholar 

Kudo M. All stages of Hepatocellular Carcinoma patients Benefit from systemic therapy combined with Locoregional Therapy. Liver Cancer. 2023;12(5):395–404.

Article  PubMed  PubMed Central  Google Scholar 

Xin Y, Zhang X, Liu N, Peng G, Huang X, Cao X, Zhou X, Li X. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma. Hepatol Int. 2023;17(3):753–64.

Article  CAS  PubMed  Google Scholar 

Wu JY, Wu JY, Li YN, Qiu FN, Zhou SQ, Yin ZY, Chen YF, Li B, Zhou JY, Yan ML. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: a multicenter retrospective study. Front Oncol. 2022;12:985380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lang M, Gan L, Ren S, Han R, Ma X, Li G, Li H, Zhang T, Wu Q, Cui Y, et al. Lenvatinib plus Sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study. Am J Cancer Res. 2023;13(6):2540–53.

CAS  PubMed  PubMed Central  Google Scholar 

Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, Zhou J, Lin L, Cao B, Chen Y, et al. Transarterial Chemoembolization Combined with Lenvatinib Plus PD-1 inhibitor for Advanced Hepatocellular Carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH, Qin YY, Zheng YT, et al. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. Hepatol Res. 2022;52(8):721–9.

Article  CAS  PubMed  Google Scholar 

Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169–78.

Article  PubMed  Google Scholar 

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.

Article  PubMed  PubMed Central  Google Scholar 

Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794–802.

Article  PubMed  Google Scholar 

Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperth. 2014;30(8):531–9.

Article  CAS  Google Scholar 

Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, Sun M, Wen W, Dai X, Yang M, et al. PD-1 blockade boosts Radiofrequency ablation-elicited adaptive Immune responses against Tumor. Clin Cancer Res. 2016;22(5):1173–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou C, Li Y, Li J, Song B, Li H, Liang B, Gu S, Li H, Chen C, Li S, et al. A phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab alone for previously treated Unresectable Hepatocellular Carcinoma. Clin Cancer Res. 2023;29(15):2816–25.

Article  CAS  PubMed  Google Scholar 

Wang L, Wang H, Cui Y, Liu M, Jin K, Xu D, Wang K, Xing B. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: a phase 2 study. Front Oncol. 2023;13:1115109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fagnoni FF, Zerbini A, Pelosi G, Missale G. Combination of radiofrequency ablation and immunotherapy. Front Biosci. 2008;13:369–81.

Article